Takeda: Lymphoma, Non-Hodgkin trials
The registry lists 10 Lymphoma, Non-Hodgkin studies with Takeda as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 6Phase 2 4Phase 3 1Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin LymphomaTerminatedNCT04074330Phase 1/2Results posted
- A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaTerminatedNCT02954406Phase 1Results posted
- Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"CompletedNCT02139592Results posted
- A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell LymphomaCompletedNCT01950364Phase 1Results posted
- Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaCompletedNCT01909934Phase 4Results posted
- Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin LymphomaCompletedNCT01492088Phase 1/2Results posted
- Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's LymphomaCompletedNCT00807495Phase 2Results posted
- Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT00312845Phase 3Results posted
- Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid TumorsWithdrawnNCT04260009Phase 1/2
- Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.CompletedNCT00298779Phase 1